Indranil Chatterjee1*, Toumica Ghosh1, Sanchari Chatterjee1, Suman Kumar Nath1, Rakhi Bakuli2 and Soumitra Sahana3
1Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India
2Assistant Professor, P.G Institute of Medical Sciences, Chandrakona Town, Paschim Midnapore, West Bengal, India
3B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India
*Corresponding Author: Indranil Chatterjee, Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India.
Received: July 06, 2020; Published: August 18, 2020
Extreme intense respiratory disorder coronavirus 2 (SARS-CoV-2), the infection that causes coronavirus illness 2019 (Covid-19), has created an overall pandemic. The interference of its spread relies upon a blend of pharmacologic and nonpharmacologic intercessions. Beigel., et al. have given in the Journal the principal report of a powerful treatment for Covid-19, coming about because of a thoroughly structured and led clinical trial .
It is surprising that a randomized, fake treatment controlled preliminary of a possible antiviral treatment for an infection whose pathogenesis is as yet not completely characterized was done at numerous global locales during a pandemic.
Citation: Indranil Chatterjee., et al. “Remdesivir and Hydroxychloroquine: An Important First Step of Searching for Evidence to Prevent COVID-19 (SARS-CoV-2)". Acta Scientific Microbiology 3.9 (2020): 23-26.
Copyright: © 2020 Indranil Chatterjee., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.